Goldman Sachs Reaffirms Their Hold Rating on Pro Medicus Limited (PMCUF)

In a report released on January 23, Chris Cooper from Goldman Sachs maintained a Hold rating on Pro Medicus Limited (PMCUFResearch Report), with a price target of A$51.60. The company’s shares closed last Monday at $44.51.

According to TipRanks, Cooper is a 2-star analyst with an average return of 1.5% and a 52.00% success rate.

The word on The Street in general, suggests a Hold analyst consensus rating for Pro Medicus Limited with a $41.52 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $44.51 and a one-year low of $25.74. Currently, Pro Medicus Limited has an average volume of 622.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pro Medicus Ltd is a health imaging IT provider. The company provides a comprehensive range of health imaging software and services to hospitals, imaging centres and health care groups worldwide. The product line comprises solutions for RIS (Radiology Information Systems) /Practice Management, Healthcare Imaging, and e-health. Pro Medicus also offers software applications for medical accounting, clinical reporting, appointments/scheduling and marketing/management. The business is spread across North America, Australia, and Europe.

Read More on PMCUF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More